: The AMEDEO Literature Guide

Home The Word Brain

My Amedeo

FAQ

Privacy

About

Flying Publisher

Oliena Studio

Stroke and language recovery: 9000+ videos

Español • Italiano • Sardu • English | PDF+

Malignant Melanoma

Free Subscription

Articles published in Melanoma Res
Retrieve available abstracts of 315 articles:
HTML format
Text format

Single Articles

October 2019

JOHANSSON PA, Nathan V, Bourke LM, Palmer JM, et al
Evaluation of the contribution of germline variants in BRCA1 and BRCA2 to uveal and cutaneous melanoma.
Melanoma Res. 2019;29:483-490.
PubMed Text format Abstract available

September 2019

SALGADO C, Kwesi-Maliepaard EM, Jochemsen AG, Visser M, et al
A novel germline variant in the DOT1L gene co-segregating in a Dutch family with a history of melanoma.
Melanoma Res. 2019 Sep 12. doi: 10.1097/CMR.0000000000000640.
PubMed Text format Abstract available

SAXENA R, Wang Y, Mier JW
CXCR4 inhibition modulates the tumor microenvironment and retards the growth of B16-OVA melanoma and Renca tumors.
Melanoma Res. 2019 Sep 12. doi: 10.1097/CMR.0000000000000639.
PubMed Text format Abstract available

August 2019

MORENO-ARRONES OM, Zegeer J, Gerbo M, Manrique-Silva E, et al
Decreased vitamin D serum levels at melanoma diagnosis are associated with tumor ulceration and high tumor mitotic rate.
Melanoma Res. 2019 Aug 28. doi: 10.1097/CMR.0000000000000638.
PubMed Text format Abstract available

PRIOR L, Toomey S, Greally M, Keane F, et al
Genomic profiling of a dedifferentiated mucosal melanoma following exposure to immunotherapy.
Melanoma Res. 2019 Aug 14. doi: 10.1097/CMR.0000000000000636.
PubMed Text format Abstract available

SORICH MJ, Rowland A, Hopkins AM
Validation of dabrafenib-trametinib prognostic groups in patients treated with vemurafenib and cobimetinib for advanced BRAF-mutated melanoma.
Melanoma Res. 2019 Aug 14. doi: 10.1097/CMR.0000000000000634.
PubMed Text format Abstract available

POSTOW MA, Chasalow SD, Kuk D, Panageas KS, et al
Absolute lymphocyte count as a prognostic biomarker for overall survival in patients with advanced melanoma treated with ipilimumab.
Melanoma Res. 2019 Aug 14. doi: 10.1097/CMR.0000000000000633.
PubMed Text format Abstract available

HUSSAIN RN, Heimann H, Damato B
Neoadjuvant intravitreal ranibizumab treatment in high-risk ocular melanoma patients: a two-stage single-centre phase II single-arm study.
Melanoma Res. 2019 Aug 14. doi: 10.1097/CMR.0000000000000635.
PubMed Text format

MAIEZZA S, Greliak A, Rached HA, Mortier L, et al
Exacerbation of skin psoriasis when associating an MEK inhibitor with anti-PD1 immunotherapy for metastatic melanoma.
Melanoma Res. 2019;29:447-448.
PubMed Text format

MARCE D, Cornillier H, Denis C, Jonville-Bera AP, et al
Partial response of metastatic melanoma to BRAF-inhibitor-monotherapy in a pregnant patient with no fetal toxicity.
Melanoma Res. 2019;29:446-447.
PubMed Text format

RAYNER JE, McMeniman EK, Duffy DL, De'Ambrosis B, et al
IRF4 rs12203592*T/T genotype is associated with nodular melanoma.
Melanoma Res. 2019;29:445-446.
PubMed Text format

KOHLMANN J, Kirsten H, Simon JC, Ziemer M, et al
Refined common terminology criteria for adverse events criteria - respective systemic melanoma therapy.
Melanoma Res. 2019;29:444-445.
PubMed Text format

July 2019

HU H, Li Z, Zhou Y, Zhang Y, et al
GLT8D1 overexpression as a novel prognostic biomarker in human cutaneous melanoma.
Melanoma Res. 2019 Jul 11. doi: 10.1097/CMR.0000000000000631.
PubMed Text format Abstract available

MALKHASYAN KA, Rooney SL, Snow AN, Swick BL, et al
The clinical characteristics of melanoma with BRAF V600R mutation: a case series study.
Melanoma Res. 2019 Jul 11. doi: 10.1097/CMR.0000000000000630.
PubMed Text format Abstract available

GUTIERREZ-CASTANEDA LD, Nova JA, Tovar-Parra JD
Frequency of mutations in BRAF, NRAS, and KIT in different populations and histological subtypes of melanoma: a systemic review.
Melanoma Res. 2019 Jul 3. doi: 10.1097/CMR.0000000000000628.
PubMed Text format Abstract available

June 2019

ANDERSON KL, Snyder KM, Ito D, Lins DC, et al
Evolutionarily conserved resistance to phagocytosis observed in melanoma cells is insensitive to upregulation of pro-phagocytic signals and to CD47 blockade.
Melanoma Res. 2019 Jun 12. doi: 10.1097/CMR.0000000000000629.
PubMed Text format Abstract available

STRBENAC D, Wang K, Wang X, Dong J, et al
Melanoma Explorer: a web application to allow easy reanalysis of publicly available and clinically annotated melanoma omics data sets.
Melanoma Res. 2019;29:342-344.
PubMed Text format Abstract available

PLAQUEVENT M, Greliak A, Pinard C, Duval-Modeste AB, et al
Simultaneous long-lasting regression of multiple nevi and melanoma metastases after ipilimumab therapy.
Melanoma Res. 2019;29:311-312.
PubMed Text format Abstract available

WILSON MA, Zhong J, Rosenbaum BE, Utter K, et al
Impact of initial stage on metastatic melanoma survival.
Melanoma Res. 2019;29:281-288.
PubMed Text format Abstract available

MANRIQUE-SILVA E, Reyes-Garcia D, Traves V, Rachakonda S, et al
TERT promoter mutation subtypes in 20 in-situ melanomas.
Melanoma Res. 2019;29:347-348.
PubMed Text format

FERNANDEZ-DIAZ AB, Garcia-Medina A, Ferrer-Guillen B, Berrocal A, et al
Eye immune privilege? Nivolumab plus ipilimumab: successful treatment in a patient with cutaneous melanoma and ocular metastases.
Melanoma Res. 2019;29:345-347.
PubMed Text format

FERNANDEZ-SARTORIO C, Alos L, Garcia-Herrera A, Ferrando J, et al
Multiple primary melanoma with the Meyerson phenomenon in a young patient.
Melanoma Res. 2019;29:325-327.
PubMed Text format Abstract available

GAUCI ML, Boudou P, Squara PA, Delyon J, et al
Checkpoint inhibitor treatment induces an increase in HbA1c in nondiabetic patients.
Melanoma Res. 2019;29:328-332.
PubMed Text format Abstract available

May 2019

DIAMANTOPOULOS PT, Lakiotaki E, Kyriakakis G, Gogas H, et al
New primary melanoma in a patient under triple therapy with vemurafenib, cobimetinib, and atezolizumab for metastatic melanoma.
Melanoma Res. 2019 May 30. doi: 10.1097/CMR.0000000000000627.
PubMed Text format Abstract available

ZULEGER CL, Newton MA, Ma X, Ong IM, et al
Enrichment of melanoma-associated T cells in 6-thioguanine-resistant T cells from metastatic melanoma patients.
Melanoma Res. 2019 May 23. doi: 10.1097/CMR.0000000000000625.
PubMed Text format Abstract available

KOMINA AV, Palkina NV, Aksenenko MB, Lavrentev SN, et al
Semaphorin-5A downregulation is associated with enhanced migration and invasion of BRAF-positive melanoma cells under vemurafenib treatment in melanomas with heterogeneous BRAF status.
Melanoma Res. 2019 May 20. doi: 10.1097/CMR.0000000000000621.
PubMed Text format Abstract available

DUGGAN MC, Regan-Fendt K, Olaverria Salavaggione GN, Howard JH, et al
Neuroblastoma RAS viral oncogene homolog mRNA is differentially spliced to give five distinct isoforms: implications for melanoma therapy.
Melanoma Res. 2019 May 20. doi: 10.1097/CMR.0000000000000623.
PubMed Text format Abstract available

PISTONI M, Tondelli G, Gallo C, Torricelli F, et al
Exploring metabolic reprogramming in melanoma via acquired resistance to the oxidative phosphorylation inhibitor phenformin.
Melanoma Res. 2019 May 20. doi: 10.1097/CMR.0000000000000624.
PubMed Text format Abstract available

REN Y, Lv Q, Yue W, Liu B, et al
The programmed cell death protein-1/programmed cell death ligand 1 expression, CD3+ T cell infiltration, NY-ESO-1 expression, and microsatellite instability phenotype in primary cutaneous melanoma and mucosal melanoma and their clinical significance a
Melanoma Res. 2019 May 14. doi: 10.1097/CMR.0000000000000620.
PubMed Text format Abstract available

MENZIES SW, Liyanarachchi S, Coates E, Smith A, et al
Estimated risk of progression of lentigo maligna to lentigo maligna melanoma.
Melanoma Res. 2019 May 14. doi: 10.1097/CMR.0000000000000619.
PubMed Text format Abstract available

MARTIN-ALGARRA S, Hinshelwood R, Mesnage S, Cebon J, et al
Effectiveness of dabrafenib in the treatment of patients with BRAF V600-mutated metastatic melanoma in a Named Patient Program.
Melanoma Res. 2019 May 14. doi: 10.1097/CMR.0000000000000608.
PubMed Text format Abstract available

HAGGSTROM L, Duong TA, Thomas B, Brungs D, et al
Disseminated intravascular coagulation and melanoma: a novel case occurring in metastatic melanoma with BRAF and NRAS mutations and systematic review.
Melanoma Res. 2019 May 14. doi: 10.1097/CMR.0000000000000622.
PubMed Text format Abstract available

NAMIKAWA K, Takahashi A, Mori T, Tsutsumida A, et al
Nivolumab for patients with metastatic uveal melanoma previously untreated with ipilimumab: a single-institution retrospective study.
Melanoma Res. 2019 May 14. doi: 10.1097/CMR.0000000000000617.
PubMed Text format Abstract available

SCATOZZA F, D'Arcangelo D, Giampietri C, Facchiano F, et al
Melanogenesis and autophagy in melanoma.
Melanoma Res. 2019 May 14. doi: 10.1097/CMR.0000000000000615.
PubMed Text format

April 2019

AUTIER P, Dore JF
Ultraviolet radiation and cutaneous melanoma: a historical perspective.
Melanoma Res. 2019 Apr 8. doi: 10.1097/CMR.0000000000000609.
PubMed Text format Abstract available

KOHLMANN J, Wagenknecht D, Simon JC, Ziemer M, et al
Immune-related pancreatitis associated with checkpoint blockade in melanoma.
Melanoma Res. 2019 Apr 5. doi: 10.1097/CMR.0000000000000611.
PubMed Text format Abstract available

MARIC H, Supic G, Kandolf-Sekulovic L, Maric V, et al
DNMT1 and DNMT3B genetic polymorphisms affect the clinical course and outcome of melanoma patients.
Melanoma Res. 2019 Apr 3. doi: 10.1097/CMR.0000000000000612.
PubMed Text format Abstract available

STERA S, Balermpas P, Blanck O, Wolff R, et al
Stereotactic radiosurgery combined with immune checkpoint inhibitors or kinase inhibitors for patients with multiple brain metastases of malignant melanoma.
Melanoma Res. 2019;29:187-195.
PubMed Text format Abstract available

MAURER DM, Butterfield LH, Vujanovic L
Melanoma vaccines: clinical status and immune endpoints.
Melanoma Res. 2019;29:109-118.
PubMed Text format Abstract available

March 2019

NEELAM S, Mellon J, Wilkerson A, Niederkorn JY, et al
Defective FasL expression is associated with increased resistance to melanoma liver metastases and enhanced natural killer cell activity.
Melanoma Res. 2019 Mar 29. doi: 10.1097/CMR.0000000000000614.
PubMed Text format Abstract available

MIKKELSEN LH, Andersen MK, Andreasen S, Larsen AC, et al
Global microRNA profiling of metastatic conjunctival melanoma.
Melanoma Res. 2019 Mar 29. doi: 10.1097/CMR.0000000000000606.
PubMed Text format Abstract available

BLANKENSTEIN SA, van Akkooi ACJ
Adjuvant systemic therapy in high-risk melanoma.
Melanoma Res. 2019 Mar 20. doi: 10.1097/CMR.0000000000000604.
PubMed Text format Abstract available

LIANG L, Zhang Z, Qin X, Gao Y, et al
Long noncoding RNA ZFAS1 promotes tumorigenesis through regulation of miR-150-5p/RAB9A in melanoma.
Melanoma Res. 2019 Mar 18. doi: 10.1097/CMR.0000000000000595.
PubMed Text format Abstract available

GRATZ V, Langan EA, Neumann A, Zillikens D, et al
Acute neurological adverse events during immune checkpoint inhibition therapy in patients with melanoma brain metastases.
Melanoma Res. 2019 Mar 11. doi: 10.1097/CMR.0000000000000597.
PubMed Text format Abstract available

ORLANDI E, Chiara Z, Albino P, Morena N, et al
Lack of association of metastasis-associated lung adenocarcinoma transcript 1 variants with melanoma skin cancer risk.
Melanoma Res. 2019 Mar 11. doi: 10.1097/CMR.0000000000000605.
PubMed Text format Abstract available

MANGANA J, Dimitriou F, Braun R, Ludwig S, et al
Single-center real-life experience with low-dose ipilimumab monotherapy in adjuvant setting for patients with stage III melanoma.
Melanoma Res. 2019 Mar 11. doi: 10.1097/CMR.0000000000000593.
PubMed Text format Abstract available

OUWERKERK W, van den Berg M, van der Niet S, Limpens J, et al
Biomarkers, measured during therapy, for response of melanoma patients to immune checkpoint inhibitors: a systematic review.
Melanoma Res. 2019 Mar 7. doi: 10.1097/CMR.0000000000000589.
PubMed Text format Abstract available

MOHN N, Suhs KW, Gingele S, Angela Y, et al
Acute progressive neuropathy-myositis-myasthenia-like syndrome associated with immune-checkpoint inhibitor therapy in patients with metastatic melanoma.
Melanoma Res. 2019 Mar 6. doi: 10.1097/CMR.0000000000000598.
PubMed Text format Abstract available

KIANMEHR Z, Khorsandi K, Mohammadi M, Hosseinzadeh R, et al
Low-level laser irradiation potentiates anticancer activity of p-coumaric acid against human malignant melanoma cells.
Melanoma Res. 2019 Mar 6. doi: 10.1097/CMR.0000000000000603.
PubMed Text format Abstract available

NUNES TWN, Filippi-Chiela EC, Callegari-Jacques SM, da Silva VD, et al
Nuclear morphometric analysis in tissue as an objective tool with potential use to improve melanoma staging.
Melanoma Res. 2019 Mar 4. doi: 10.1097/CMR.0000000000000594.
PubMed Text format Abstract available

SWAMI U, Monga V, Freesmeier M, Zhang W, et al
Exceptional responses with sequential metronomic temozolomide after pembrolizumab failure in patients with metastatic melanoma.
Melanoma Res. 2019 Mar 1. doi: 10.1097/CMR.0000000000000592.
PubMed Text format Abstract available

February 2019

DRYSDALE E, Peng Y, Nguyen P, Baetz T, et al
A population-based study of the treatment effect of first-line ipilimumab for metastatic or unresectable melanoma.
Melanoma Res. 2019 Feb 14. doi: 10.1097/CMR.0000000000000582.
PubMed Text format Abstract available

BLAKEWAY EA, Elshimy N, Muinonen-Martin A, Marples M, et al
Cutaneous lupus associated with pembrolizumab therapy for advanced melanoma: a report of three cases.
Melanoma Res. 2019 Feb 11. doi: 10.1097/CMR.0000000000000587.
PubMed Text format Abstract available

DAHAL U, Kang L, Gupta M
RNA m6A methyltransferase METTL3 regulates invasiveness of melanoma cells by matrix metallopeptidase 2.
Melanoma Res. 2019 Feb 11. doi: 10.1097/CMR.0000000000000580.
PubMed Text format Abstract available

SZASZ I, Koroknai V, Kiss T, Vizkeleti L, et al
Molecular alterations associated with acquired resistance to BRAFV600E targeted therapy in melanoma cells.
Melanoma Res. 2019 Feb 6. doi: 10.1097/CMR.0000000000000588.
PubMed Text format Abstract available

BOSELLO F, Al-Jamal RT, Cohen VML
Very late recurrence of iris melanoma: 45 years after treatment.
Melanoma Res. 2019 Feb 5. doi: 10.1097/CMR.0000000000000581.
PubMed Text format Abstract available

XU W, Moor RJ, Walpole ET, Atkinson VG, et al
Pregnancy with successful foetal and maternal outcome in a melanoma patient treated with nivolumab in the first trimester: case report and review of the literature.
Melanoma Res. 2019 Feb 5. doi: 10.1097/CMR.0000000000000586.
PubMed Text format Abstract available

DIMITRIOU F, Mangana J, Micaletto S, Braun RP, et al
Cytokine release syndrome as an important differential diagnosis of severe skin toxicity with organ damage during switch from immunotherapy to targeted therapy in metastatic melanoma.
Melanoma Res. 2019;29:107-108.
PubMed Text format

YANG J, Price MA, Wanshura LEC, He J, et al
Chondroitin sulfate proteoglycan 4 enhanced melanoma motility and growth requires a cysteine in the core protein transmembrane domain.
Melanoma Res. 2019 Feb 1. doi: 10.1097/CMR.0000000000000574.
PubMed Text format Abstract available

MIR R, Shaw HM, Nathan PD
Mycophenolate mofetil alongside high-dose corticosteroids: optimizing the management of combination immune checkpoint inhibitor-induced colitis.
Melanoma Res. 2019;29:102-106.
PubMed Text format Abstract available

SEREMET T, Haccuria A, Lienard D, Del Marmol V, et al
Anaphylaxis-like reaction to anti-BRAF inhibitor dabrafenib confirmed by drug provocation test.
Melanoma Res. 2019;29:95-98.
PubMed Text format Abstract available

January 2019

IACONO D, Basile D, Gerratana L, Vitale MG, et al
Prognostic role of disease extent and lymphocyte-monocyte ratio in advanced melanoma.
Melanoma Res. 2019 Jan 29. doi: 10.1097/CMR.0000000000000584.
PubMed Text format Abstract available

STENEHJEM DD, Au TH, Ngorsuraches S, Ma J, et al
Immunotargeted therapy in melanoma: patient, provider preferences, and willingness to pay at an academic cancer center.
Melanoma Res. 2019 Jan 25. doi: 10.1097/CMR.0000000000000572.
PubMed Text format Abstract available

MARASIGAN V, Guvenc C, van den Oord JJ, Stas M, et al
Melanoma susceptibility variant rs869330 in the MTAP gene is associated with melanoma outcome.
Melanoma Res. 2019 Jan 23. doi: 10.1097/CMR.0000000000000578.
PubMed Text format Abstract available

GONG HZ, Zheng HY, Li J
Amelanotic melanoma.
Melanoma Res. 2019 Jan 21. doi: 10.1097/CMR.0000000000000571.
PubMed Text format Abstract available

RANTALA ES, Hernberg M, Kivela TT
Overall survival after treatment for metastatic uveal melanoma: a systematic review and meta-analysis.
Melanoma Res. 2019 Jan 16. doi: 10.1097/CMR.0000000000000575.
PubMed Text format Abstract available

JAARSMA-COES MG, Goncalves Ferreira TA, van Haren GR, Marinkovic M, et al
MRI enables accurate diagnosis and follow-up in uveal melanoma patients after vitrectomy.
Melanoma Res. 2019 Jan 16. doi: 10.1097/CMR.0000000000000568.
PubMed Text format Abstract available

PAN B, Lin X, Zhang L, Hong W, et al
Long noncoding RNA X-inactive specific transcript promotes malignant melanoma progression and oxaliplatin resistance.
Melanoma Res. 2019 Jan 11. doi: 10.1097/CMR.0000000000000560.
PubMed Text format Abstract available

YANG Y, Zhe H, Massoumi R, Ke H, et al
Decreased expression of nemo-like kinase in melanoma is correlated with increased vascularity and metastasis.
Melanoma Res. 2019 Jan 10. doi: 10.1097/CMR.0000000000000576.
PubMed Text format Abstract available

KHURANA S, Baldeo C, Joseph RW
Inositol hexaphosphate plus inositol induced complete remission in stage IV melanoma: a case report.
Melanoma Res. 2019 Jan 5. doi: 10.1097/CMR.0000000000000577.
PubMed Text format Abstract available

MOTOFEI IG
Melanoma and autoimmunity: spontaneous regressions as a possible model for new therapeutic approaches.
Melanoma Res. 2019 Jan 4. doi: 10.1097/CMR.0000000000000573.
PubMed Text format Abstract available

TIO D, Kasiem FR, Willemsen M, van Doorn R, et al
Expression of cancer/testis antigens in cutaneous melanoma: a systematic review.
Melanoma Res. 2019 Jan 4. doi: 10.1097/CMR.0000000000000569.
PubMed Text format Abstract available

MANCINI S, Crocetti E, Bucchi L, Pimpinelli N, et al
Time trends and age-period-cohort analysis of cutaneous malignant melanoma incidence rates in the Romagna Region (northern Italy), 1986-2014.
Melanoma Res. 2019 Jan 4. doi: 10.1097/CMR.0000000000000570.
PubMed Text format Abstract available

December 2018

BAFALOUKOS D, Papaxoinis G, Linardou H, Diamantopoulos P, et al
Prognostic significance of distant metastasis-free interval in patients with relapsed melanoma treated with BRAF with or without MEK inhibitors.
Melanoma Res. 2018 Dec 28. doi: 10.1097/CMR.0000000000000562.
PubMed Text format Abstract available

LEE WJ, Lee MH, Kim HT, Won CH, et al
Prognostic significance of CD163 expression and its correlation with cyclooxygenase-2 and vascular endothelial growth factor expression in cutaneous melanoma.
Melanoma Res. 2018 Dec 19. doi: 10.1097/CMR.0000000000000549.
PubMed Text format Abstract available

CRINCOLI E, Moliterni E, Catania F, Didona D, et al
Correlation of serum tryptase levels with total number of nevi, Breslow thickness, ulceration, and mitotic index in melanoma patients: evaluation of a promising prognostic marker.
Melanoma Res. 2018 Dec 15. doi: 10.1097/CMR.0000000000000561.
PubMed Text format Abstract available

BOURSI B, Werner TJ, Gholami S, Margalit O, et al
Physiologic colonic fluorine-18-fluorodeoxyglucose uptake may predict response to immunotherapy in patients with metastatic melanoma.
Melanoma Res. 2018 Dec 14. doi: 10.1097/CMR.0000000000000566.
PubMed Text format Abstract available

OTTES VASCONCELOS R, Serini S, de Souza Votto AP, Santos Trindade G, et al
Combination of omega-3 fatty acids and cisplatin as a potential alternative strategy for personalized therapy of metastatic melanoma: an in-vitro study.
Melanoma Res. 2018 Dec 13. doi: 10.1097/CMR.0000000000000564.
PubMed Text format Abstract available

MAHAPATRA L, Andruska N, Mao C, Gruber SB, et al
Protein kinase C-alpha is upregulated by IMP1 in melanoma and is linked to poor survival.
Melanoma Res. 2018 Dec 12. doi: 10.1097/CMR.0000000000000558.
PubMed Text format Abstract available

CORAZZA M, Dika E, Maietti E, Musmeci D, et al
Eruptive cherry angiomas and skin melanoma: a fortuitous association?
Melanoma Res. 2018 Dec 12. doi: 10.1097/CMR.0000000000000563.
PubMed Text format Abstract available

BLOCK MS, Nevala WK, Pang YP, Allred JB, et al
A pilot clinical trial testing topical resiquimod and a xenopeptide as immune adjuvants for a melanoma vaccine targeting MART-1.
Melanoma Res. 2018 Dec 4. doi: 10.1097/CMR.0000000000000556.
PubMed Text format Abstract available

CIMMINIELLO C, Indini A, Di Guardo L, Prisciandaro M, et al
Pembrolizumab in the treatment of advanced/metastatic melanoma: a single-center institution experience.
Melanoma Res. 2018 Dec 4. doi: 10.1097/CMR.0000000000000539.
PubMed Text format Abstract available

A unique gene expression signature is significantly differentially expressed in tumor-positive or tumor-negative sentinel lymph nodes in patients with melanoma: Erratum.
Melanoma Res. 2018;28:655.
PubMed Text format

November 2018

DISANO JA, Huffnagle I, Gowda R, Spiegelman VS, et al
Loss of miR-155 upregulates WEE1 in metastatic melanoma.
Melanoma Res. 2018 Nov 29. doi: 10.1097/CMR.0000000000000545.
PubMed Text format Abstract available

YANG J, Chen S, Li Y, Wang B, et al
Incidence rate and risk factors for suicide death in patients with skin malignant melanoma: a Surveillance, Epidemiology, and End Results analysis.
Melanoma Res. 2018 Nov 26. doi: 10.1097/CMR.0000000000000559.
PubMed Text format Abstract available

YAN J, Xu L, Yu J, Wu X, et al
Prognostic role of NRAS isoforms in Chinese melanoma patients.
Melanoma Res. 2018 Nov 26. doi: 10.1097/CMR.0000000000000557.
PubMed Text format Abstract available

BIANCONI F, Crocetti E, Grisci C, Primieri C, et al
What has changed in the epidemiology of skin melanoma in central Italy during the past 20 years?
Melanoma Res. 2018 Nov 26. doi: 10.1097/CMR.0000000000000551.
PubMed Text format Abstract available

HU Y, Wang Q, Zhu XH
MiR-135b is a novel oncogenic factor in cutaneous melanoma by targeting LATS2.
Melanoma Res. 2018 Nov 21. doi: 10.1097/CMR.0000000000000524.
PubMed Text format Abstract available

SARUBI HC, Pereira NB, Gomes CC, Gomez RS, et al
Molecular and immunohistochemical analyses of uveal melanoma patient cohort.
Melanoma Res. 2018 Nov 21. doi: 10.1097/CMR.0000000000000523.
PubMed Text format Abstract available

WU K, Wang W, Ye Y, Huang J, et al
Integration of protein interaction and gene co-expression information for identification of melanoma candidate genes.
Melanoma Res. 2018 Nov 19. doi: 10.1097/CMR.0000000000000525.
PubMed Text format Abstract available

ROMANO S, D'Arrigo P, Tufano M, Staibano S, et al
TRAF2 and FKBP51 as possible markers for identification of suitable melanoma tumors for tumor necrosis factor-alpha inhibition.
Melanoma Res. 2018 Nov 19. doi: 10.1097/CMR.0000000000000553.
PubMed Text format Abstract available

URBONAS V, Smailyte G, Urbonaite GV, Dulskas A, et al
Natural killer cell-based immunotherapy: a new fighter against melanoma?
Melanoma Res. 2018 Nov 19. doi: 10.1097/CMR.0000000000000552.
PubMed Text format Abstract available

MASCITTI M, Santarelli A, Sartini D, Rubini C, et al
Analysis of nicotinamide N-methyltransferase in oral malignant melanoma and potential prognostic significance.
Melanoma Res. 2018 Nov 13. doi: 10.1097/CMR.0000000000000548.
PubMed Text format Abstract available

DUNDR P, Simon K, Nemejcova K, Bartu M, et al
Stathmin is a potential therapeutic target but not a prognostic marker in melanoma: an immunohistochemical study of 323 melanocytic lesions.
Melanoma Res. 2018 Nov 12. doi: 10.1097/CMR.0000000000000550.
PubMed Text format Abstract available

SALMI S, Siiskonen H, Sironen R, Tyynela-Korhonen K, et al
The number and localization of CD68+ and CD163+ macrophages in different stages of cutaneous melanoma.
Melanoma Res. 2018 Nov 5. doi: 10.1097/CMR.0000000000000522.
PubMed Text format Abstract available

YANG N, Lu J, Lu Y, Guo J, et al
Primary malignant melanotic melanoma and hypomelanotic melanoma of the female urethra: case series and a review of the literature in China.
Melanoma Res. 2018 Nov 2. doi: 10.1097/CMR.0000000000000521.
PubMed Text format Abstract available

SACHPEKIDIS C, Kopp-Schneider A, Hakim-Meibodi L, Dimitrakopoulou-Strauss A, et al
18F-FDG PET/CT longitudinal studies in patients with advanced metastatic melanoma for response evaluation of combination treatment with vemurafenib and ipilimumab.
Melanoma Res. 2018 Nov 1. doi: 10.1097/CMR.0000000000000541.
PubMed Text format Abstract available

October 2018

PEPIN F, Julien AS, Fugaru I, Lihimdi N, et al
Regression rate of choroidal melanoma following iodine-125 brachytherapy is not associated with metastatic spread.
Melanoma Res. 2018 Oct 31. doi: 10.1097/CMR.0000000000000540.
PubMed Text format Abstract available

ABBOTT JL, Qureshi MM, Truong MT, Sahni D, et al
Comparing survival outcomes in early stage desmoplastic melanoma with or without adjuvant radiation.
Melanoma Res. 2018 Oct 31. doi: 10.1097/CMR.0000000000000532.
PubMed Text format Abstract available

ZHANG D, Wang Z, Shang D, Yu J, et al
Incidence and prognosis of brain metastases in cutaneous melanoma patients: a population-based study.
Melanoma Res. 2018 Oct 30. doi: 10.1097/CMR.0000000000000538.
PubMed Text format Abstract available

DRAGO JZ, Lawrence D, Livingstone E, Zimmer L, et al
Clinical experience with combination BRAF/MEK inhibitors for melanoma with brain metastases: a real-life multicenter study.
Melanoma Res. 2018 Oct 29. doi: 10.1097/CMR.0000000000000527.
PubMed Text format Abstract available

BUYUKKAPU BAY S, Kebudi R, Zulfikar B
Cutaneous adverse event associated with vemurafenib in a 3-year-old pediatric patient with BRAF mutation-positive metastatic melanoma and factor X deficiency.
Melanoma Res. 2018 Oct 29. doi: 10.1097/CMR.0000000000000537.
PubMed Text format Abstract available

VUJIC I, Gandini S, Stanganelli I, Fierro MT, et al
A meta-analysis of melanoma risk in industrial workers.
Melanoma Res. 2018 Oct 26. doi: 10.1097/CMR.0000000000000531.
PubMed Text format Abstract available

MARCOVAL J, Sabate-Llobera A, Bermejo J, Fornons-Servent R, et al
Hibernoma as an incidental finding in the 18F-FDG PET/CT of a patient with melanoma.
Melanoma Res. 2018 Oct 24. doi: 10.1097/CMR.0000000000000530.
PubMed Text format Abstract available

ABDEL-RAHMAN O
Population-based validation of the National Cancer Comprehensive Network recommendations for baseline imaging workup of cutaneous melanoma.
Melanoma Res. 2018 Oct 22. doi: 10.1097/CMR.0000000000000528.
PubMed Text format Abstract available

BELLOCQ D, Roy P, Kodjikian L, Mathis T, et al
20-year assessment of metastatic latency and subsequent time to death after proton therapy for uveal melanomas.
Melanoma Res. 2018 Oct 12. doi: 10.1097/CMR.0000000000000519.
PubMed Text format Abstract available

VAN LAAR RK, Lincoln MT, van Laar BJ
A plasma microRNA biomarker of melanoma as a personalised assessment of treatment response.
Melanoma Res. 2018 Oct 12. doi: 10.1097/CMR.0000000000000492.
PubMed Text format Abstract available

PETRELLI F, Ardito R, Merelli B, Lonati V, et al
Prognostic and predictive role of elevated lactate dehydrogenase in patients with melanoma treated with immunotherapy and BRAF inhibitors: a systematic review and meta-analysis.
Melanoma Res. 2018 Oct 10. doi: 10.1097/CMR.0000000000000520.
PubMed Text format Abstract available

DABROSIN N, Sloth Juul K, Baehr Georgsen J, Andrup S, et al
Innate immune cell infiltration in melanoma metastases affects survival and is associated with BRAFV600E mutation status.
Melanoma Res. 2018 Oct 5. doi: 10.1097/CMR.0000000000000515.
PubMed Text format Abstract available

LASKE J, Meier F, Bauer A, Beissert S, et al
Tattoo-associated complications of metastatic melanoma treated with dabrafenib and trametinib.
Melanoma Res. 2018;28:485-487.
PubMed Text format

September 2018

HALFPENNY NJA, Scott DA, Thompson JC, Gurung B, et al
A practical approach to predict expansion of evidence networks: a case study in treatment-naive advanced melanoma.
Melanoma Res. 2018 Sep 29. doi: 10.1097/CMR.0000000000000513.
PubMed Text format Abstract available

HWANG SJE, Park JJW, Wakade D, Chou S, et al
Cutaneous adverse events of anti-programmed death 1 antibodies combined with anti-cytotoxic T-lymphocyte-associated protein 4 therapy use in patients with metastatic melanoma.
Melanoma Res. 2018 Sep 29. doi: 10.1097/CMR.0000000000000518.
PubMed Text format Abstract available

YIP RHL, Lee LH, Schaeffer DF, Horst BA, et al
Lymphocytic gastritis induced by pembrolizumab in a patient with metastatic melanoma.
Melanoma Res. 2018 Sep 25. doi: 10.1097/CMR.0000000000000502.
PubMed Text format Abstract available

YIN G, Guo W, Chen X, Huang Z, et al
Prognosis of endoscopic surgery and traditional open resection in mucosal melanoma of the nasal cavity and paranasal sinus.
Melanoma Res. 2018 Sep 25. doi: 10.1097/CMR.0000000000000516.
PubMed Text format Abstract available

GHATE S, Ionescu-Ittu R, Burne R, Ndife B, et al
Patterns of treatment and BRAF testing with immune checkpoint inhibitors and targeted therapy in patients with metastatic melanoma presumed to be BRAF positive.
Melanoma Res. 2018 Sep 21. doi: 10.1097/CMR.0000000000000504.
PubMed Text format Abstract available

SCAINI MC, Pigozzo J, Pizzi M, Manicone M, et al
Clonal heterogeneity of melanoma in a paradigmatic case study: future prospects for circulating melanoma cells.
Melanoma Res. 2018 Sep 14. doi: 10.1097/CMR.0000000000000510.
PubMed Text format Abstract available

TINGFENG X, Fuqiang P, Dong L
Expression and clinical significance of S100 family genes in patients with melanoma.
Melanoma Res. 2018 Sep 13. doi: 10.1097/CMR.0000000000000512.
PubMed Text format Abstract available

TARHINI A, Ghate SR, Ionescu-Ittu R, Manceur AM, et al
Postsurgical treatment landscape and economic burden of locoregional and distant recurrence in patients with operable nonmetastatic melanoma.
Melanoma Res. 2018 Sep 13. doi: 10.1097/CMR.0000000000000507.
PubMed Text format Abstract available

SHAH S, Luke JJ, Jacene HA, Chen T, et al
Results from phase II trial of HSP90 inhibitor, STA-9090 (ganetespib), in metastatic uveal melanoma.
Melanoma Res. 2018 Sep 11. doi: 10.1097/CMR.0000000000000509.
PubMed Text format Abstract available

SEREMET T, Planken S, Schwarze JK, Jansen Y, et al
Successful treatment with intralesional talimogene laherparepvec in two patients with immune checkpoint inhibitors refractory advanced melanoma.
Melanoma Res. 2018 Sep 11. doi: 10.1097/CMR.0000000000000501.
PubMed Text format Abstract available

CHRISTENSEN L, Scott J, Bordeaux J
Use of gene expression profile testing as a prognostic tool in early-stage cutaneous melanoma - compelling but not ready for primetime.
Melanoma Res. 2018 Sep 11. doi: 10.1097/CMR.0000000000000506.
PubMed Text format Abstract available

DE MELO AC, Wainstein AJA, Buzaid AC, Thuler LCS, et al
Melanoma signature in Brazil: epidemiology, incidence, mortality, and trend lessons from a continental mixed population country in the past 15 years.
Melanoma Res. 2018 Sep 10. doi: 10.1097/CMR.0000000000000511.
PubMed Text format Abstract available

ZHAO B, Cheng X, Zhou X
The BET-bromodomain inhibitor JQ1 mitigates vemurafenib drug resistance in melanoma.
Melanoma Res. 2018 Sep 5. doi: 10.1097/CMR.0000000000000497.
PubMed Text format Abstract available

TROMME I, Sacre L, Hammouch F, Richez P, et al
Melanoma diagnosis: predictive value of macroscopic changes observed by the patient.
Melanoma Res. 2018 Sep 5. doi: 10.1097/CMR.0000000000000496.
PubMed Text format Abstract available

NYE A, Collins JD, Porter CL, Montes de Oca M, et al
Predictive genetic profiles for regional lymph node metastasis in primary cutaneous melanoma: a case-matched pilot study.
Melanoma Res. 2018 Sep 1. doi: 10.1097/CMR.0000000000000499.
PubMed Text format Abstract available

August 2018

KANG R, Lipner S
Assessment of internet sources on subungual melanoma.
Melanoma Res. 2018 Aug 30. doi: 10.1097/CMR.0000000000000508.
PubMed Text format Abstract available

TAN SY, Najita J, Li X, Strazzulla LC, et al
Clinicopathologic features correlated with paradoxical outcomes in stage IIC versus IIIA melanoma patients.
Melanoma Res. 2018 Aug 30. doi: 10.1097/CMR.0000000000000483.
PubMed Text format Abstract available

DIAMANTOPOULOS PT, Stoungioti S, Anastasopoulou A, Papaxoinis G, et al
Incomplete Vogt-Koyanagi-Harada disease following treatment with encorafenib and binimetinib for metastatic melanoma.
Melanoma Res. 2018 Aug 30. doi: 10.1097/CMR.0000000000000505.
PubMed Text format Abstract available

SWORDS DS, Andtbacka RHI, Bowles TL, Hyngstrom JR, et al
Routine retrieval of pelvic sentinel lymph nodes for melanoma rarely adds prognostic information or alters management.
Melanoma Res. 2018 Aug 29. doi: 10.1097/CMR.0000000000000498.
PubMed Text format Abstract available

KENESSEY I, Kramer Z, Istvan L, Cserepes MT, et al
Inhibition of epidermal growth factor receptor improves antitumor efficacy of vemurafenib in BRAF-mutant human melanoma in preclinical model.
Melanoma Res. 2018 Aug 17. doi: 10.1097/CMR.0000000000000488.
PubMed Text format Abstract available

HERBERT A, Koo MM, Barclay ME, Greenberg DC, et al
Stage-specific incidence trends of melanoma in an English region, 1996-2015: longitudinal analyses of population-based data.
Melanoma Res. 2018 Aug 13. doi: 10.1097/CMR.0000000000000489.
PubMed Text format Abstract available

YAN J, Wu X, Yu J, Ma M, et al
Establishment and characterization of melanoma patient-derived xenograft models for preclinical evaluation of novel therapeutics.
Melanoma Res. 2018 Aug 6. doi: 10.1097/CMR.0000000000000494.
PubMed Text format Abstract available

GROGAN N, Swami U, Bossler AD, Zakharia Y, et al
Toxicities with targeted therapies after immunotherapy in metastatic melanoma.
Melanoma Res. 2018 Aug 6. doi: 10.1097/CMR.0000000000000493.
PubMed Text format Abstract available

LIU G, Wang Y, Fei F, Wang X, et al
Clinical characteristics and preliminary morphological observation of 47 cases of primary anorectal malignant melanomas.
Melanoma Res. 2018 Aug 3. doi: 10.1097/CMR.0000000000000491.
PubMed Text format Abstract available

MONTAUDIE H, Picard A, Panaia-Ferrari P, Boukari F, et al
Painful acute thyroiditis following a first cure of Ipilimumab plus Nivolumab for metastatic melanoma.
Melanoma Res. 2018;28:368-369.
PubMed Text format

July 2018

NICHOLAS MN, Khoja L, Atenafu EG, Hogg D, et al
Prognostic factors for first-line therapy and overall survival of metastatic uveal melanoma: The Princess Margaret Cancer Centre experience.
Melanoma Res. 2018 Jul 31. doi: 10.1097/CMR.0000000000000468.
PubMed Text format Abstract available

SUN H, Chen Y, Chen Y, Liu D, et al
Primary malignant melanoma of the cervix: 14 cases and literature overview.
Melanoma Res. 2018 Jul 23. doi: 10.1097/CMR.0000000000000469.
PubMed Text format Abstract available

AYDOGMUS-OZTURK F, Gunaydin K, Ozturk M, Jahan H, et al
Effect of Sideritis leptoclada against HT-144 human malignant melanoma.
Melanoma Res. 2018 Jul 19. doi: 10.1097/CMR.0000000000000487.
PubMed Text format Abstract available

SAGLAM O, Naqvi SMH, Zhang Y, Mesa T, et al
Female genitourinary tract melanoma: mutation analysis with clinicopathologic correlation: a single-institution experience.
Melanoma Res. 2018 Jul 19. doi: 10.1097/CMR.0000000000000480.
PubMed Text format Abstract available

BORGOGNONI L, Bellucci F, Urso C, Manneschi G, et al
Enhancing the prognostic role of melanoma sentinel lymph nodes through microscopic tumour burden characterization: clinical usefulness in patients who do not undergo complete lymph node dissection.
Melanoma Res. 2018 Jul 17. doi: 10.1097/CMR.0000000000000481.
PubMed Text format Abstract available

NUNES LF, Quintella Mendes GL, Koifman RJ
Acral melanoma: a retrospective cohort from the Brazilian National Cancer Institute (INCA).
Melanoma Res. 2018 Jul 16. doi: 10.1097/CMR.0000000000000476.
PubMed Text format Abstract available

OLAVERRIA SALAVAGGIONE GN, Duggan MC, Carson WE
Analysis of MLN4924 (pevonedistat) as a potential therapeutic agent in malignant melanoma.
Melanoma Res. 2018 Jul 16. doi: 10.1097/CMR.0000000000000474.
PubMed Text format Abstract available

BRUNSSEN A, Jansen L, Eisemann N, Waldmann A, et al
Long-term relative survival from melanoma in Germany 1997-2013.
Melanoma Res. 2018 Jul 16. doi: 10.1097/CMR.0000000000000482.
PubMed Text format Abstract available

HUTCHINSON PE, Halsall JA, Popovici S, Papadogeorgakis E, et al
Compromised vitamin D receptor signalling in malignant melanoma is associated with tumour progression and mitogen-activated protein kinase activity.
Melanoma Res. 2018 Jul 12. doi: 10.1097/CMR.0000000000000475.
PubMed Text format Abstract available

FERRIS LK, Gerami P, Skelsey MK, Peck G, et al
Real-world performance and utility of a noninvasive gene expression assay to evaluate melanoma risk in pigmented lesions.
Melanoma Res. 2018 Jul 12. doi: 10.1097/CMR.0000000000000478.
PubMed Text format Abstract available

LYTH J
Conditional recurrence-free survival in patients with primary stage I-II cutaneous malignant melanoma - a population-based study.
Melanoma Res. 2018 Jul 9. doi: 10.1097/CMR.0000000000000479.
PubMed Text format Abstract available

LAMIAUX M, Scalbert C, Lepesant P, Desmedt E, et al
Severe skin toxicity with organ damage under the combination of targeted therapy following immunotherapy in metastatic melanoma.
Melanoma Res. 2018 Jul 6. doi: 10.1097/CMR.0000000000000472.
PubMed Text format Abstract available

GORLOV I, Orlow I, Ringelberg C, Hernando E, et al
Identification of gene expression levels in primary melanoma associated with clinically meaningful characteristics.
Melanoma Res. 2018 Jul 2. doi: 10.1097/CMR.0000000000000473.
PubMed Text format Abstract available

GOMEZ-LEON N, Pacheco-Barcia V, Ballesteros AI, Fraga J, et al
Skeletal muscle and solitary bone metastases from malignant melanoma: multimodality imaging and oncological outcome.
Melanoma Res. 2018 Jul 2. doi: 10.1097/CMR.0000000000000466.
PubMed Text format Abstract available

June 2018

URBONAS V, Smailyte G
Combination of cytokine-directed and anti-programmed cell death protein 1 therapy - a new attractive option in melanoma treatment?
Melanoma Res. 2018 Jun 29. doi: 10.1097/CMR.0000000000000470.
PubMed Text format Abstract available

RAMBHIA PH, Honda K, Arbesman J
Nivolumab induced inflammation of seborrheic keratoses: a novel cutaneous manifestation in a metastatic melanoma patient.
Melanoma Res. 2018 Jun 29. doi: 10.1097/CMR.0000000000000477.
PubMed Text format Abstract available

MENSHAWY A, Eltonob AA, Barkat SA, Ghanem A, et al
Nivolumab monotherapy or in combination with ipilimumab for metastatic melanoma: systematic review and meta-analysis of randomized-controlled trials.
Melanoma Res. 2018 Jun 27. doi: 10.1097/CMR.0000000000000467.
PubMed Text format Abstract available

PUZA CJ, Barbas AS, Mosca PJ
Outcomes of patients with a pretransplant history of early-stage melanoma.
Melanoma Res. 2018 Jun 25. doi: 10.1097/CMR.0000000000000471.
PubMed Text format Abstract available

MORGADO-CARRASCO D, Moreno-Rivera N, Fusta-Novell X, Garcia-Herrera A, et al
Histiocytoid Sweet's syndrome during combined therapy with BRAF and MEK inhibitors for metastatic melanoma.
Melanoma Res. 2018;28:256-257.
PubMed Text format

May 2018

HAFLIGER EM, Ramelyte E, Mangana J, Kunz M, et al
Metastatic acral lentiginous melanoma in a tertiary referral center in Switzerland: a systematic analysis.
Melanoma Res. 2018 May 29. doi: 10.1097/CMR.0000000000000465.
PubMed Text format Abstract available

IACONO D, Cinausero M, Gerratana L, Angione V, et al
Tumour-infiltrating lymphocytes, programmed death ligand 1 and cyclooxygenase-2 expression in skin melanoma of elderly patients: clinicopathological correlations.
Melanoma Res. 2018 May 22. doi: 10.1097/CMR.0000000000000462.
PubMed Text format Abstract available

BRUTTING J, Bergmann M, Garzarolli M, Rauschenberg R, et al
Unmet information needs of patients with melanoma in Germany.
Melanoma Res. 2018 May 21. doi: 10.1097/CMR.0000000000000464.
PubMed Text format Abstract available

TETERYCZ P, Jagodzinska-Mucha P, Cybulska-Stopa B, Mariuk-Jarema A, et al
High baseline neutrophil-to-lymphocyte ratio predicts worse outcome in patients with metastatic BRAF-positive melanoma treated with BRAF and MEK inhibitors.
Melanoma Res. 2018 May 18. doi: 10.1097/CMR.0000000000000461.
PubMed Text format Abstract available

FACINA AS, Facina G, Guerreiro da Silva IDC, Correa SAA, et al
Pregnancy and the apoptotic pathway in experimental melanoma.
Melanoma Res. 2018 May 17. doi: 10.1097/CMR.0000000000000452.
PubMed Text format Abstract available

ZHOU X, Zeng Y, Jiang H, Xia L, et al
Predictive value of excision repair cross-complementing group 2 gene Lys751Gln and Asp312Asn polymorphisms in melanoma risk.
Melanoma Res. 2018 May 15. doi: 10.1097/CMR.0000000000000463.
PubMed Text format Abstract available

TSOUTSOS D, Papadopoulos S, Kehagias G, Mara A, et al
Epidemiological trends in the diagnosis of melanoma in a Southern European population: analysis of a large database from a tertiary referral center.
Melanoma Res. 2018 May 14. doi: 10.1097/CMR.0000000000000456.
PubMed Text format Abstract available

AFZAL MZ, Shirai K
Immune checkpoint inhibitor (anti-CTLA-4, anti-PD-1) therapy alone versus immune checkpoint inhibitor (anti-CTLA-4, anti-PD-1) therapy in combination with anti-RANKL denosumuab in malignant melanoma: a retrospective analysis at a tertiary care center.
Melanoma Res. 2018 May 10. doi: 10.1097/CMR.0000000000000459.
PubMed Text format Abstract available

TENGDA L, Shuping L, Mingli G, Jie G, et al
Serum exosomal microRNAs as potent circulating biomarkers for melanoma.
Melanoma Res. 2018 May 10. doi: 10.1097/CMR.0000000000000450.
PubMed Text format Abstract available

ASCIERTO PA, Bastholt L, Ferrucci PF, Hansson J, et al
The impact of patient characteristics and disease-specific factors on first-line treatment decisions for BRAF-mutated melanoma: results from a European expert panel study.
Melanoma Res. 2018 May 10. doi: 10.1097/CMR.0000000000000455.
PubMed Text format Abstract available

MOSHE M, Levi A, Ad-El D, Ben-Amitai D, et al
Malignant melanoma clinically mimicking pyogenic granuloma: comparison of clinical evaluation and histopathology.
Melanoma Res. 2018 May 10. doi: 10.1097/CMR.0000000000000451.
PubMed Text format Abstract available

SCHOUWENBURG MG, Jochems A, Leeneman B, Franken MG, et al
Vemurafenib in BRAF-mutant metastatic melanoma patients in real-world clinical practice: prognostic factors associated with clinical outcomes.
Melanoma Res. 2018 May 10. doi: 10.1097/CMR.0000000000000453.
PubMed Text format Abstract available

GONG HZ, Zheng HY, Li J
The clinical significance of KIT mutations in melanoma: a meta-analysis.
Melanoma Res. 2018 May 9. doi: 10.1097/CMR.0000000000000454.
PubMed Text format Abstract available

April 2018

SEBESTYEN T, Mohos A, Liszkay G, Somlai B, et al
Correlation with lymphocyte infiltration, but lack of prognostic significance of MECA-79-positive high endothelial venules in primary malignant melanoma.
Melanoma Res. 2018 Apr 20. doi: 10.1097/CMR.0000000000000457.
PubMed Text format Abstract available

LEE WJ, Lee YJ, Shin HJ, Won CH, et al
Clinicopathological significance of tumor-infiltrating lymphocytes and programmed death-1 expression in cutaneous melanoma: a comparative study on clinical subtypes.
Melanoma Res. 2018 Apr 9. doi: 10.1097/CMR.0000000000000449.
PubMed Text format Abstract available

SIA DIT, Thaung C, O'Hanlon-Brown C, Cohen VML, et al
Immune privilege: failure of immunotherapy in controlling metastatic cutaneous melanoma to the eye.
Melanoma Res. 2018 Apr 9. doi: 10.1097/CMR.0000000000000443.
PubMed Text format Abstract available

BASSOLI S, Pellegrini C, Longo C, Di Nardo L, et al
Clinical, dermoscopic, and confocal features of nevi and melanomas in a multiple primary melanoma patient with the MITF p.E318K homozygous mutation.
Melanoma Res. 2018;28:166-169.
PubMed Text format

TAKAHASHI A, Tsutsumida A, Namikawa K, Yamazaki N, et al
Fulminant type 1 diabetes associated with nivolumab in a patient with metastatic melanoma.
Melanoma Res. 2018;28:159-160.
PubMed Text format

FERNANDEZ-SARTORIO C, Boada A, Chavez-Bourgeois MM, Ruiz Ares GJ, et al
Aged-looking skin and encorafenib: an adverse event of BRAF inhibitors.
Melanoma Res. 2018;28:160-162.
PubMed Text format

MUTO Y, Ng W, Namikawa K, Takahashi A, et al
Success of rechallenging dabrafenib and trametinib combination therapy after trametinib-induced rhabdomyolysis: a case report.
Melanoma Res. 2018;28:151-154.
PubMed Text format Abstract available

March 2018

TURNER KA, Manouchehri JM, Kalafatis M
Sensitization of recombinant human tumor necrosis factor-related apoptosis-inducing ligand-resistant malignant melanomas by quercetin.
Melanoma Res. 2018 Mar 28. doi: 10.1097/CMR.0000000000000447.
PubMed Text format Abstract available

TERNOV NK, Lambine TL, Wagenblast ALH, Clasen-Linde E, et al
Targeted ultrasound and fine-needle aspiration cytology for sentinel node diagnostics in early-stage melanoma: a validation study.
Melanoma Res. 2018 Mar 27. doi: 10.1097/CMR.0000000000000448.
PubMed Text format Abstract available

CHESNEY J, Imbert-Fernandez Y, Telang S, Baum M, et al
Potential clinical and immunotherapeutic utility of talimogene laherparepvec for patients with melanoma after disease progression on immune checkpoint inhibitors and BRAF inhibitors.
Melanoma Res. 2018 Mar 21. doi: 10.1097/CMR.0000000000000444.
PubMed Text format Abstract available

KLEEMANN J, Hrgovic I, Ter-Nedden J, Kleimann P, et al
Fatty acid receptor GPR120: a novel marker for human melanoma.
Melanoma Res. 2018 Mar 21. doi: 10.1097/CMR.0000000000000445.
PubMed Text format Abstract available

LADE-KELLER J, Yuusufi S, Riber-Hansen R, Steiniche T, et al
Telomerase reverse transcriptase promoter mutations and solar elastosis in cutaneous melanoma.
Melanoma Res. 2018 Mar 21. doi: 10.1097/CMR.0000000000000446.
PubMed Text format Abstract available

NASARRE P, Bonilla IV, Metcalf JS, Hilliard EG, et al
TRAF3-interacting protein 3, a new oncotarget, promotes tumor growth in melanoma.
Melanoma Res. 2018 Mar 16. doi: 10.1097/CMR.0000000000000440.
PubMed Text format Abstract available

GESKIN LJ, Damiano JJ, Patrone CC, Butterfield LH, et al
Three antigen-loading methods in dendritic cell vaccines for metastatic melanoma.
Melanoma Res. 2018 Mar 14. doi: 10.1097/CMR.0000000000000441.
PubMed Text format Abstract available

DE UNAMUNO B, Garcia-Casado Z, Banuls J, Requena C, et al
CDKN2A germline alterations in melanoma patients with personal or familial history of pancreatic cancer.
Melanoma Res. 2018 Mar 14. doi: 10.1097/CMR.0000000000000442.
PubMed Text format Abstract available

STOWMAN AM, Hickman AW, Mauldin IS, Mahmutovic A, et al
Lymphoid aggregates in desmoplastic melanoma have features of tertiary lymphoid structures.
Melanoma Res. 2018 Mar 13. doi: 10.1097/CMR.0000000000000439.
PubMed Text format Abstract available

FOLEY KC, Nishimura MI, Moore TV
Combination immunotherapies implementing adoptive T-cell transfer for advanced-stage melanoma.
Melanoma Res. 2018 Mar 8. doi: 10.1097/CMR.0000000000000436.
PubMed Text format Abstract available

February 2018

MACHIRAJU D, Moll I, Gebhardt C, Sucker A, et al
STAT5 expression correlates with recurrence and survival in melanoma patients treated with interferon-alpha.
Melanoma Res. 2018 Feb 26. doi: 10.1097/CMR.0000000000000435.
PubMed Text format Abstract available

DIMITRIOU F, Frauchiger AL, Urosevic-Maiwald M, Naegeli MC, et al
Sarcoid-like reactions in patients receiving modern melanoma treatment.
Melanoma Res. 2018 Feb 26. doi: 10.1097/CMR.0000000000000437.
PubMed Text format Abstract available

GONZALEZ-CAO M, Mayo de Las Casas C, Jordana Ariza N, Manzano JL, et al
Early evolution of BRAFV600 status in the blood of melanoma patients correlates with clinical outcome and identifies patients refractory to therapy.
Melanoma Res. 2018 Feb 23. doi: 10.1097/CMR.0000000000000432.
PubMed Text format Abstract available

TESTORI AA, Suciu S, van Akkooi ACJ, Suppa M, et al
Lymph node ratio as a prognostic factor in melanoma: results from European Organization for Research and Treatment of Cancer 18871, 18952, and 18991 studies.
Melanoma Res. 2018 Feb 9. doi: 10.1097/CMR.0000000000000433.
PubMed Text format Abstract available

GANZETTI G, Sartini D, Campanati A, Rubini C, et al
Nicotinamide N-methyltransferase: potential involvement in cutaneous malignant melanoma.
Melanoma Res. 2018 Feb 7. doi: 10.1097/CMR.0000000000000430.
PubMed Text format Abstract available

YANAGITA M, Luke JJ, Hodi FS, Janne PA, et al
Isolation and characterization of circulating melanoma cells by size filtration and fluorescent in-situ hybridization.
Melanoma Res. 2018 Feb 5. doi: 10.1097/CMR.0000000000000431.
PubMed Text format Abstract available

KOTHAPALLI A, Khattak MA
Safety and efficacy of anti-PD-1 therapy for metastatic melanoma and non-small-cell lung cancer in patients with viral hepatitis: a case series.
Melanoma Res. 2018 Feb 5. doi: 10.1097/CMR.0000000000000434.
PubMed Text format Abstract available

EISENSTEIN A, Panova IP, Chung HJ, Goldberg LJ, et al
Quantitative assessment of neuropilin-2 as a simple and sensitive diagnostic assay for spitzoid melanocytic lesions.
Melanoma Res. 2018;28:71-75.
PubMed Text format Abstract available

ISAKOVIC AM, Petricevic SM, Ristic SM, Popadic DM, et al
In vitro and in vivo antimelanoma effect of ethyl ester cyclohexyl analog of ethylenediamine dipropanoic acid.
Melanoma Res. 2018;28:8-20.
PubMed Text format Abstract available

January 2018

GEUKES FOPPEN MH, Boogerd W, Blank CU, van Thienen JV, et al
Clinical and radiological response of BRAF inhibition and MEK inhibition in patients with brain metastases from BRAF-mutated melanoma.
Melanoma Res. 2018 Jan 19. doi: 10.1097/CMR.0000000000000429.
PubMed Text format Abstract available

NARDIN C, Mateus C, Texier M, Lanoy E, et al
Tolerance and outcomes of stereotactic radiosurgery combined with anti-programmed cell death-1 (pembrolizumab) for melanoma brain metastases.
Melanoma Res. 2018 Jan 19. doi: 10.1097/CMR.0000000000000413.
PubMed Text format Abstract available

ROSE AM, Radia UK, Luo R, Kalirai H, et al
Multiple primary malignancies and prolonged survival in a patient with widespread metastatic cutaneous melanoma.
Melanoma Res. 2018 Jan 17. doi: 10.1097/CMR.0000000000000426.
PubMed Text format

ZHU W, Li S, Zou B, Liu H, et al
Expressions and clinical significance of HER4 and CD44 in sinonasal mucosal malignant melanoma.
Melanoma Res. 2018 Jan 5. doi: 10.1097/CMR.0000000000000428.
PubMed Text format Abstract available

DANISH H, Ferris MJ, Balagamwala E, Switchenko JM, et al
Comparative outcomes and toxicities for ruthenium-106 versus palladium-103 in the treatment of choroidal melanoma.
Melanoma Res. 2018 Jan 3. doi: 10.1097/CMR.0000000000000420.
PubMed Text format Abstract available

December 2017

DEL CARPIO HUERTA LP, Mas Castells M, Anguera Palacios G, Sullivan I, et al
A novel KRAS mutation in metastasic conjunctival melanoma: a case report and literature review.
Melanoma Res. 2017 Dec 20. doi: 10.1097/CMR.0000000000000423.
PubMed Text format Abstract available

WEITMAN ES, Perez M, Thompson JF, Andtbacka RHI, et al
Quality of life patient-reported outcomes for locally advanced cutaneous melanoma.
Melanoma Res. 2017 Dec 19. doi: 10.1097/CMR.0000000000000425.
PubMed Text format Abstract available

GALLO S, Coha V, Caravelli D, Becco P, et al
BRAF-inhibitors can exert control of disease in BRAF T599I mutated melanoma: a case report.
Melanoma Res. 2017 Dec 11. doi: 10.1097/CMR.0000000000000417.
PubMed Text format Abstract available

BISSCHOP C, Ter Elst A, Bosman LJ, Platteel I, et al
Rapid BRAF mutation tests in patients with advanced melanoma: comparison of immunohistochemistry, Droplet Digital PCR, and the Idylla Mutation Platform.
Melanoma Res. 2017 Dec 11. doi: 10.1097/CMR.0000000000000421.
PubMed Text format Abstract available

SEREMET T, Planken S, Schreuer M, Jansen Y, et al
Illustrative cases for monitoring by quantitative analysis of BRAF/NRAS ctDNA mutations in liquid biopsies of metastatic melanoma patients who gained clinical benefits from anti-PD1 antibody therapy.
Melanoma Res. 2017 Dec 8. doi: 10.1097/CMR.0000000000000415.
PubMed Text format Abstract available

LOYSON T, Werbrouck E, Punie K, Bonne L, et al
Hemorrhage of liver and bone metastases as a result of rapid response to dual BRAF/MEK inhibition in metastatic melanoma: a case report.
Melanoma Res. 2017 Dec 5. doi: 10.1097/CMR.0000000000000419.
PubMed Text format Abstract available

MENZIES S, Barry R, Ormond P
Multiple primary melanoma: a single centre retrospective review.
Melanoma Res. 2017;27:638-640.
PubMed Text format Abstract available

SCHINZARI G, Rossi E, Cassano A, Dadduzio V, et al
Cisplatin, dacarbazine and vinblastine as first line chemotherapy for liver metastatic uveal melanoma in the era of immunotherapy: a single institution phase II study.
Melanoma Res. 2017;27:591-595.
PubMed Text format Abstract available

HALLMEYER S, Gonzalez R, Lawson DH, Cranmer LD, et al
Vemurafenib treatment for patients with locally advanced, unresectable stage IIIC or metastatic melanoma and activating exon 15 BRAF mutations other than V600E.
Melanoma Res. 2017;27:585-590.
PubMed Text format Abstract available

ROBINSON JP, Rebecca VW, Kircher DA, Silvis MR, et al
Resistance mechanisms to genetic suppression of mutant NRAS in melanoma.
Melanoma Res. 2017;27:545-557.
PubMed Text format Abstract available

VAN DER WEYDEN L, Arends MJ, Brenn T, Tuting T, et al
Widespread spontaneous hyperproliferation, melanosis and melanoma in Hgf-Cdk4R24C mice.
Melanoma Res. 2017 Dec 1. doi: 10.1097/CMR.0000000000000414.
PubMed Text format

November 2017

BRANCA M, Orso S, Molinari RC, Xu H, et al
Is nonmetastatic cutaneous melanoma predictable through genomic biomarkers?
Melanoma Res. 2017 Nov 29. doi: 10.1097/CMR.0000000000000412.
PubMed Text format Abstract available

CHESNEY J, Awasthi S, Curti B, Hutchins L, et al
Phase IIIb safety results from an expanded-access protocol of talimogene laherparepvec for patients with unresected, stage IIIB-IVM1c melanoma.
Melanoma Res. 2017 Nov 22. doi: 10.1097/CMR.0000000000000399.
PubMed Text format Abstract available

HADDEN NJ, McIntosh JRD, Jay S, Whittaker PJ, et al
Prognostic factors in patients with metastatic spinal cord compression secondary to melanoma: a systematic review.
Melanoma Res. 2017 Nov 14. doi: 10.1097/CMR.0000000000000411.
PubMed Text format Abstract available

KUO JC, Lilly LB, Hogg D
Immune checkpoint inhibitor therapy in a liver transplant recipient with a rare subtype of melanoma: a case report and literature review.
Melanoma Res. 2017 Nov 14. doi: 10.1097/CMR.0000000000000410.
PubMed Text format Abstract available

BRZOZOWSKA M, Wierzba W, Sliwczynski A, Swierkowski M, et al
Analysis of survival of patients treated with vemurafenib, ipilimumab and dabrafenib for advanced skin melanoma in daily clinical practice (Real-World Data): retrospective analysis of patients treated under drug/reimbursement programmes in Poland in 2
Melanoma Res. 2017 Nov 8. doi: 10.1097/CMR.0000000000000408.
PubMed Text format Abstract available

October 2017

PACHMANN K, Willecke-Hochmuth R, Schneider K, Kaatz M, et al
Circulating epithelial tumor cells as a prognostic tool for malignant melanoma.
Melanoma Res. 2017 Oct 25. doi: 10.1097/CMR.0000000000000407.
PubMed Text format Abstract available

TANG Y, Xie C, Zhang Y, Qin Y, et al
Overexpression of mRNA-decapping enzyme 1a predicts disease-specific survival in malignant melanoma.
Melanoma Res. 2017 Oct 25. doi: 10.1097/CMR.0000000000000406.
PubMed Text format Abstract available

UPRETY D, Bista A, Chennamadhavuni A, Niroula A, et al
Survival trends among patients with metastatic melanoma in the pretargeted and the post-targeted era: a US population-based study.
Melanoma Res. 2017 Oct 11. doi: 10.1097/CMR.0000000000000394.
PubMed Text format Abstract available

FAILING JJ, Yan Y, Porrata LF, Markovic SN, et al
Lymphocyte-to-monocyte ratio is associated with survival in pembrolizumab-treated metastatic melanoma patients.
Melanoma Res. 2017 Oct 9. doi: 10.1097/CMR.0000000000000404.
PubMed Text format Abstract available

SHEN X, Fan Y, Cao S
A review of primary malignant melanoma arising in an ovarian cystic teratoma.
Melanoma Res. 2017 Oct 9. doi: 10.1097/CMR.0000000000000402.
PubMed Text format Abstract available

ALESSI C, Scapulatempo Neto C, Viana CR, Vazquez VL, et al
PD-1/PD-L1 and VEGF-A/VEGF-C expression in lymph node microenvironment and association with melanoma metastasis and survival.
Melanoma Res. 2017 Oct 3. doi: 10.1097/CMR.0000000000000396.
PubMed Text format Abstract available

TSIOGKA A, Jansky GL, Bauer JW, Koelblinger P, et al
Fulminant type 1 diabetes after adjuvant ipilimumab therapy in cutaneous melanoma.
Melanoma Res. 2017;27:524-525.
PubMed Text format

ABOUDARAM A, Modesto A, Chaltiel L, Gomez-Roca C, et al
Concurrent radiotherapy for patients with metastatic melanoma and receiving anti-programmed-death 1 therapy: a safe and effective combination.
Melanoma Res. 2017;27:485-491.
PubMed Text format Abstract available

September 2017

MARTINEZ-GARCIA MA, Riveiro-Falkenbach E, Rodriguez-Peralto JL, Nagore E, et al
A prospective multicenter cohort study of cutaneous melanoma: clinical staging and potential associations with HIF-1alpha and VEGF expressions.
Melanoma Res. 2017 Sep 6. doi: 10.1097/CMR.0000000000000393.
PubMed Text format Abstract available

DE SOUZA NETO FP, Bernardes SS, Marinello PC, Melo GP, et al
Metformin: oxidative and proliferative parameters in-vitro and in-vivo models of murine melanoma.
Melanoma Res. 2017 Sep 4. doi: 10.1097/CMR.0000000000000391.
PubMed Text format Abstract available

YUKI A, Takenouchi T, Takatsuka S, Ishiguro T, et al
A case of pure red cell aplasia during nivolumab therapy for cardiac metastatic melanoma.
Melanoma Res. 2017 Sep 1. doi: 10.1097/CMR.0000000000000392.
PubMed Text format Abstract available

TAHA T, Tzuk-Shina T, Forschner I, Bar-Sela G, et al
Acute motor and sensory axonal neuropathy related to treatment with MEK inhibitors in a patient with advanced melanoma.
Melanoma Res. 2017 Sep 1. doi: 10.1097/CMR.0000000000000390.
PubMed Text format Abstract available

August 2017

LI Y, Umbach DM, Li L
Putative genomic characteristics of BRAF V600K versus V600E cutaneous melanoma.
Melanoma Res. 2017 Aug 28. doi: 10.1097/CMR.0000000000000388.
PubMed Text format Abstract available

TARHINI AA, Floros T, Lin HM, Lin Y, et al
A unique gene expression signature is significantly differentially expressed in tumor-positive or tumor-negative sentinel lymph nodes in patients with melanoma.
Melanoma Res. 2017 Aug 18. doi: 10.1097/CMR.0000000000000383.
PubMed Text format Abstract available

GLITZA IC, Guha-Thakurta N, D'Souza NM, Amaria RN, et al
Bevacizumab as an effective treatment for radiation necrosis after radiotherapy for melanoma brain metastases.
Melanoma Res. 2017 Aug 16. doi: 10.1097/CMR.0000000000000389.
PubMed Text format Abstract available

PURI A, Homsi J
The safety of pembrolizumab in metastatic melanoma and rheumatoid arthritis.
Melanoma Res. 2017 Aug 16. doi: 10.1097/CMR.0000000000000387.
PubMed Text format Abstract available

BARBARIC J, Laversanne M, Znaor A
Malignant melanoma incidence trends in a Mediterranean population following socioeconomic transition and war: results of age-period-cohort analysis in Croatia, 1989-2013.
Melanoma Res. 2017 Aug 10. doi: 10.1097/CMR.0000000000000385.
PubMed Text format Abstract available

GARDNER LJ, Ward M, Andtbacka RHI, Boucher KM, et al
Risk factors for development of melanoma brain metastasis and disease progression: a single-center retrospective analysis.
Melanoma Res. 2017 Aug 10. doi: 10.1097/CMR.0000000000000382.
PubMed Text format Abstract available

ROGIERS A, Borght SV, Tuand K, Wolter P, et al
Response to targeted therapy in two patients with metastatic melanoma carrying rare BRAF exon 15 mutations: A598_T599insV and V600_K601delinsE.
Melanoma Res. 2017 Aug 10. doi: 10.1097/CMR.0000000000000376.
PubMed Text format Abstract available

GOGAS HJ, Karalexi MA, Dessypris N, Antoniadis AG, et al
The role of depression and personality traits in patients with melanoma: a South-European study.
Melanoma Res. 2017 Aug 10. doi: 10.1097/CMR.0000000000000380.
PubMed Text format Abstract available

GLADFELTER P, Darwish NHE, Mousa SA
Current status and future direction in the management of malignant melanoma.
Melanoma Res. 2017 Aug 10. doi: 10.1097/CMR.0000000000000379.
PubMed Text format Abstract available

GRANGE F, Mohr P, Harries M, Ehness R, et al
Economic burden of advanced melanoma in France, Germany and the UK: a retrospective observational study (Melanoma Burden-of-Illness Study).
Melanoma Res. 2017 Aug 10. doi: 10.1097/CMR.0000000000000372.
PubMed Text format Abstract available

STOWMAN AM, Hickman AW, Gru AA, Slingluff CL Jr, et al
Histopathologic review of negative sentinel lymph node biopsies in thin melanomas: an argument for the routine use of immunohistochemistry.
Melanoma Res. 2017;27:369-376.
PubMed Text format Abstract available

DE ROSA F, Ridolfi L, Fiammenghi L, Petrini M, et al
Dendritic cell vaccination for metastatic melanoma: a 14-year monoinstitutional experience.
Melanoma Res. 2017;27:351-357.
PubMed Text format Abstract available

SANGALLI A, Orlandi E, Poli A, Maurichi A, et al
Sex-specific effect of RNASEL rs486907 and miR-146a rs2910164 polymorphisms' interaction as a susceptibility factor for melanoma skin cancer.
Melanoma Res. 2017;27:309-314.
PubMed Text format Abstract available

July 2017

SOSSAU D, Kofler L, Eigentler T
Type 1 diabetes mellitus caused by treatment with low-dose interferon-alpha in a melanoma patient.
Melanoma Res. 2017 Jul 19. doi: 10.1097/CMR.0000000000000381.
PubMed Text format Abstract available

BORGHI A, Corazza M, Virgili A, Lambertini AG, et al
Impact of socioeconomic status and district of residence on cutaneous malignant melanoma prognosis: a survival study on incident cases between 1991 and 2011 in the province of Ferrara, northern Italy.
Melanoma Res. 2017 Jul 18. doi: 10.1097/CMR.0000000000000378.
PubMed Text format Abstract available

GRATZ V, Luttmann N, Haase O, Langan EA, et al
Meningeal melanomatosis following discontinuation of dabrafenib: implications for the maintenance of long-term complete remission.
Melanoma Res. 2017 Jul 18. doi: 10.1097/CMR.0000000000000373.
PubMed Text format Abstract available

GAUCI ML, Laly P, Sarah LL, Behin A, et al
Focal necrotizing myopathy with 'dropped-head syndrome' induced by cobimetinib in metastatic melanoma.
Melanoma Res. 2017 Jul 7. doi: 10.1097/CMR.0000000000000377.
PubMed Text format Abstract available

June 2017

WANDLER A, Riber-Hansen R, Hager H, Hamilton-Dutoit SJ, et al
Quantification of microRNA-21 and microRNA-125b in melanoma tissue.
Melanoma Res. 2017 Jun 13. doi: 10.1097/CMR.0000000000000374.
PubMed Text format Abstract available

TOMIZUKA T, Namikawa K, Higashi T
Characteristics of melanoma in Japan: a nationwide registry analysis 2011-2013.
Melanoma Res. 2017 Jun 12. doi: 10.1097/CMR.0000000000000375.
PubMed Text format Abstract available

SOARES CD, Borges CF, Sena-Filho M, Almeida OP, et al
Prognostic significance of cyclooxygenase 2 and phosphorylated Akt1 overexpression in primary nonmetastatic and metastatic cutaneous melanomas.
Melanoma Res. 2017 Jun 9. doi: 10.1097/CMR.0000000000000368.
PubMed Text format Abstract available

DAVICK JJ, Wick MR, Gru AA
Development of a biclonal cutaneous T-cell lymphoproliferative process during treatment with immune checkpoint inhibitors for metastatic melanoma.
Melanoma Res. 2017 Jun 1. doi: 10.1097/CMR.0000000000000371.
PubMed Text format Abstract available

GIUDICE G, Robusto F, Vestita M, Annoscia P, et al
Single-stage excision and sentinel lymph node biopsy in cutaneous melanoma in selected patients: a retrospective case-control study.
Melanoma Res. 2017 Jun 1. doi: 10.1097/CMR.0000000000000370.
PubMed Text format Abstract available

WANG Y, Wen XZ, Ba HJ, Li DD, et al
A prognostic model for resectable acral melanoma patients on the basis of preoperative inflammatory markers.
Melanoma Res. 2017 Jun 1. doi: 10.1097/CMR.0000000000000365.
PubMed Text format Abstract available

MIRZA S, Hill E, Ludlow SP, Nanjappa S, et al
Checkpoint inhibitor-associated drug reaction with eosinophilia and systemic symptom syndrome.
Melanoma Res. 2017;27:271-273.
PubMed Text format Abstract available

HAUEIS SA, Kranzlin P, Mangana J, Cheng PF, et al
Does the distribution pattern of brain metastases during BRAF inhibitor therapy reflect phenotype switching?
Melanoma Res. 2017;27:231-237.
PubMed Text format Abstract available

May 2017

FURDOVA A, Sramka M, Chorvath M, Kralik G, et al
Clinical experience of stereotactic radiosurgery at a linear accelerator for intraocular melanoma.
Melanoma Res. 2017 May 17. doi: 10.1097/CMR.0000000000000364.
PubMed Text format Abstract available

MANGANA J, Cheng PF, Kaufmann C, Amann VC, et al
Multicenter, real-life experience with checkpoint inhibitors and targeted therapy agents in advanced melanoma patients in Switzerland.
Melanoma Res. 2017 May 15. doi: 10.1097/CMR.0000000000000359.
PubMed Text format Abstract available

GUADAGNI S, Fiorentini G, Clementi M, Palumbo G, et al
MGMT methylation correlates with melphalan pelvic perfusion survival in stage III melanoma patients: a pilot study.
Melanoma Res. 2017 May 10. doi: 10.1097/CMR.0000000000000367.
PubMed Text format Abstract available

LAKHTER AJ, Naidu SR
Cyclic AMP-Epac signaling pathway contributes to repression of PUMA transcription in melanoma cells.
Melanoma Res. 2017 May 4. doi: 10.1097/CMR.0000000000000363.
PubMed Text format Abstract available

HOLTKAMP LHJ, Read RL, Emmett L, Thompson JF, et al
Futility of imaging to stage melanoma patients with a positive sentinel lymph node.
Melanoma Res. 2017 May 4. doi: 10.1097/CMR.0000000000000362.
PubMed Text format Abstract available

STABLER S, Becquart C, Dumezy F, Terriou L, et al
Hemophagocytic lymphohistiocytosis in patients with metastatic malignant melanoma.
Melanoma Res. 2017 May 3. doi: 10.1097/CMR.0000000000000354.
PubMed Text format Abstract available

April 2017

MENDT M, Cardier JE
Activation of the CXCR4 chemokine receptor enhances biological functions associated with B16 melanoma liver metastasis.
Melanoma Res. 2017 Apr 25. doi: 10.1097/CMR.0000000000000346.
PubMed Text format Abstract available

KYRGIDIS A, Lallas A, Moscarella E, Longo C, et al
Does pregnancy influence melanoma prognosis? A meta-analysis.
Melanoma Res. 2017 Apr 20. doi: 10.1097/CMR.0000000000000334.
PubMed Text format Abstract available

DIAMANTOPOULOS PT, Gaggadi M, Kassi E, Benopoulou O, et al
Late-onset nivolumab-mediated pneumonitis in a patient with melanoma and multiple immune-related adverse events.
Melanoma Res. 2017 Apr 17. doi: 10.1097/CMR.0000000000000355.
PubMed Text format Abstract available

PISCIOLI F, Pusiol T, Roncati L
Critical points of T1 stage in primary melanoma.
Melanoma Res. 2017 Apr 13. doi: 10.1097/CMR.0000000000000357.
PubMed Text format

MURER C, Kranzlin-Stieger P, French LE, Dummer R, et al
Successful treatment with imatinib after nilotinib and ipilimumab in a c-kit-mutated advanced melanoma patient: a case report.
Melanoma Res. 2017 Apr 13. doi: 10.1097/CMR.0000000000000358.
PubMed Text format Abstract available

TARHINI AA, Moschos SJ, Lin Y, Lin HM, et al
Safety and efficacy of the antiganglioside GD3 antibody ecromeximab (KW2871) combined with high-dose interferon-alpha2b in patients with metastatic melanoma.
Melanoma Res. 2017 Apr 7. doi: 10.1097/CMR.0000000000000353.
PubMed Text format Abstract available

THOMSON CH, Cassell O, Peach H, Holloway S, et al
Neuropathic pain and quality of life after wide local excision and sentinel lymph node biopsy for melanoma: a multicentre study.
Melanoma Res. 2017;27:121-125.
PubMed Text format Abstract available

ROGIERS A, Wolter P, Bechter O
Dabrafenib plus trametinib rechallenge in four melanoma patients who previously progressed on this combination.
Melanoma Res. 2017;27:164-167.
PubMed Text format Abstract available

BLACKMON JT, Dhawan R, Terry NL, Conry RM, et al
Response of BRAF inhibitor-associated squamous cell lung carcinoma to drug withdrawal.
Melanoma Res. 2017;27:159-163.
PubMed Text format Abstract available

AMODE R, Baroudjian B, Kowal A, Jebali M, et al
Anti-programmed cell death protein 1 tolerance and efficacy after ipilimumab immunotherapy: observational study of 39 patients.
Melanoma Res. 2017;27:110-115.
PubMed Text format Abstract available

March 2017

DE GIORGI V, Grazzini M, Benemei S, Marchionni N, et al
beta-Blocker use and reduced disease progression in patients with thick melanoma: 8 years of follow-up.
Melanoma Res. 2017 Mar 24. doi: 10.1097/CMR.0000000000000317.
PubMed Text format Abstract available

HINTZSCHE JD, Gorden NT, Amato CM, Kim J, et al
Whole-exome sequencing identifies recurrent SF3B1 R625 mutation and comutation of NF1 and KIT in mucosal melanoma.
Melanoma Res. 2017 Mar 14. doi: 10.1097/CMR.0000000000000345.
PubMed Text format Abstract available

LEON-FERRE RA, Kottschade LA, Block MS, McWilliams RR, et al
Association between the use of surveillance PET/CT and the detection of potentially salvageable occult recurrences among patients with resected high-risk melanoma.
Melanoma Res. 2017 Mar 14. doi: 10.1097/CMR.0000000000000344.
PubMed Text format Abstract available

CARRERA C, Gual A, Diaz A, Puig-Butille JA, et al
Prognostic role of the histological subtype of melanoma on the hands and feet in Caucasians.
Melanoma Res. 2017 Mar 14. doi: 10.1097/CMR.0000000000000340.
PubMed Text format Abstract available

FALLENI M, Savi F, Tosi D, Agape E, et al
M1 and M2 macrophages' clinicopathological significance in cutaneous melanoma.
Melanoma Res. 2017 Mar 7. doi: 10.1097/CMR.0000000000000352.
PubMed Text format Abstract available

FUKUDA K, Funakoshi T, Sakurai T, Nakamura Y, et al
Peptide-pulsed dendritic cell vaccine in combination with carboplatin and paclitaxel chemotherapy for stage IV melanoma.
Melanoma Res. 2017 Mar 3. doi: 10.1097/CMR.0000000000000342.
PubMed Text format Abstract available

BLASIG H, Bender C, Hassel JC, Eigentler TK, et al
Reinduction of PD1-inhibitor therapy: first experience in eight patients with metastatic melanoma.
Melanoma Res. 2017 Mar 2. doi: 10.1097/CMR.0000000000000341.
PubMed Text format Abstract available

DE GIORGI V, Gori A, Savarese I, D'Errico A, et al
Clinical and dermoscopic features of truly amelanotic plantar melanoma.
Melanoma Res. 2017 Mar 1. doi: 10.1097/CMR.0000000000000337.
PubMed Text format Abstract available

LOQUAI C, Schmidtmann I, Garzarolli M, Kaatz M, et al
Interactions from complementary and alternative medicine in patients with melanoma.
Melanoma Res. 2017 Mar 1. doi: 10.1097/CMR.0000000000000339.
PubMed Text format Abstract available

February 2017

DESVIGNES C, Abirached H, Templier C, Drumez E, et al
BRAF inhibitor discontinuation and rechallenge in advanced melanoma patients with a complete initial treatment response.
Melanoma Res. 2017 Feb 24. doi: 10.1097/CMR.0000000000000350.
PubMed Text format Abstract available

TAS F, Erturk K
Scalp melanoma is associated with high mitotic rate and is a poor prognostic factor for recurrence and outcome.
Melanoma Res. 2017 Feb 23. doi: 10.1097/CMR.0000000000000351.
PubMed Text format Abstract available

VIZKELETI L, Kiss T, Koroknai V, Ecsedi S, et al
Altered integrin expression patterns shown by microarray in human cutaneous melanoma.
Melanoma Res. 2017 Feb 23. doi: 10.1097/CMR.0000000000000322.
PubMed Text format Abstract available

ITCHINS M, Ascierto PA, Menzies AM, Oatley M, et al
A multireferral centre retrospective cohort analysis on the experience in treatment of metastatic uveal melanoma and utilization of sequential liver-directed treatment and immunotherapy.
Melanoma Res. 2017 Feb 22. doi: 10.1097/CMR.0000000000000343.
PubMed Text format Abstract available

MADU MF, Timmerman P, Wouters MW, van der Hiel B, et al
PET/CT surveillance detects asymptomatic recurrences in stage IIIB and IIIC melanoma patients: a prospective cohort study.
Melanoma Res. 2017 Feb 20. doi: 10.1097/CMR.0000000000000347.
PubMed Text format Abstract available

LI FJ, Li LM, Zhang RH, Xu C, et al
The role of 5-hydroxymethylcytosine in melanoma.
Melanoma Res. 2017 Feb 20. doi: 10.1097/CMR.0000000000000349.
PubMed Text format Abstract available

TESIO V, Ribero S, Castelli L, Bassino S, et al
Psychological characteristics of early-stage melanoma patients: a cross-sectional study on 204 patients.
Melanoma Res. 2017 Feb 15. doi: 10.1097/CMR.0000000000000348.
PubMed Text format Abstract available

RIBERO S, Longo C, Specchio F, Piana S, et al
Lymph nodes' capsular naevi are associated with high naevus count in melanoma patients: a case-control study.
Melanoma Res. 2017 Feb 1. doi: 10.1097/CMR.0000000000000328.
PubMed Text format Abstract available

January 2017

PELLEGRINI C, Maturo MG, Martorelli C, Suppa M, et al
Characterization of melanoma susceptibility genes in high-risk patients from Central Italy.
Melanoma Res. 2017 Jan 31. doi: 10.1097/CMR.0000000000000323.
PubMed Text format Abstract available

LINO-SILVA LS, Salcedo-Hernandez RA, Garcia-Perez L, Meneses-Garcia A, et al
Basal neutrophil-to-lymphocyte ratio is associated with overall survival in melanoma.
Melanoma Res. 2017 Jan 25. doi: 10.1097/CMR.0000000000000333.
PubMed Text format Abstract available

GRAY A, Grushchak S, Mudaliar K, Kliethermes S, et al
The microenvironment in primary cutaneous melanoma with associated spontaneous tumor regression: evaluation for T-regulatory cells and the presence of an immunosuppressive microenvironment.
Melanoma Res. 2017 Jan 25. doi: 10.1097/CMR.0000000000000331.
PubMed Text format Abstract available

OBEID JM, Hu Y, Erdag G, Leick KM, et al
The heterogeneity of tumor-infiltrating CD8+ T cells in metastatic melanoma distorts their quantification: how to manage heterogeneity?
Melanoma Res. 2017 Jan 21. doi: 10.1097/CMR.0000000000000330.
PubMed Text format Abstract available

OBA J, Esmaeli B, Ellerhorst JA, Lyons GR, et al
Trends in hepatocyte growth factor, insulin-like growth factor 1, thyroid-stimulating hormone, and leptin expression levels in uveal melanoma patient serum and tumor tissues: correlation to disease progression.
Melanoma Res. 2017 Jan 21. doi: 10.1097/CMR.0000000000000329.
PubMed Text format Abstract available

LADWA R, Atkinson V
The cessation of anti-PD-1 antibodies of complete responders in metastatic melanoma.
Melanoma Res. 2017 Jan 17. doi: 10.1097/CMR.0000000000000336.
PubMed Text format Abstract available

TAS F, Erturk K
Recurrence behavior in early-stage cutaneous melanoma: pattern, timing, survival, and influencing factors.
Melanoma Res. 2017 Jan 17. doi: 10.1097/CMR.0000000000000332.
PubMed Text format Abstract available

DE HAAN J, Lok CA, de Groot CJ, Crijns MB, et al
Melanoma during pregnancy: a report of 60 pregnancies complicated by melanoma.
Melanoma Res. 2017 Jan 17. doi: 10.1097/CMR.0000000000000327.
PubMed Text format Abstract available

LV C, Dai H, Sun M, Zhao H, et al
Mesenchymal stem cells induce epithelial mesenchymal transition in melanoma by paracrine secretion of transforming growth factor-beta.
Melanoma Res. 2017 Jan 5. doi: 10.1097/CMR.0000000000000325.
PubMed Text format Abstract available

BORRONI RG, Manganoni AM, Grassi S, Grasso M, et al
Genetic counselling and high-penetrance susceptibility gene analysis reveal the novel CDKN2A p.D84V (c.251A>T) mutation in melanoma-prone families from Italy.
Melanoma Res. 2017 Jan 4. doi: 10.1097/CMR.0000000000000324.
PubMed Text format Abstract available

December 2016

LINO-SILVA LS, Castillo-Medina AL, Salcedo-Hernandez RA, Garcia-Perez L, et al
Exhaustive pathologic work-up in sentinel lymph node biopsy for melanoma: is it necessary?
Melanoma Res. 2016 Dec 27. doi: 10.1097/CMR.0000000000000319.
PubMed Text format Abstract available

MICEVIC G, Theodosakis N, Taube JM, Bosenberg MW, et al
Attenuation of genome-wide 5-methylcytosine level is an epigenetic feature of cutaneous malignant melanomas.
Melanoma Res. 2016 Dec 16. doi: 10.1097/CMR.0000000000000315.
PubMed Text format Abstract available

BEHLING J, Kaes J, Munzel T, Grabbe S, et al
New-onset third-degree atrioventricular block because of autoimmune-induced myositis under treatment with anti-programmed cell death-1 (nivolumab) for metastatic melanoma.
Melanoma Res. 2016.
PubMed Text format Abstract available

MININI R, Rohrmann S, Braun R, Korol D, et al
Incidence trends and clinical-pathological characteristics of invasive cutaneous melanoma from 1980 to 2010 in the canton of Zurich, Switzerland.
Melanoma Res. 2016.
PubMed Text format Abstract available

PISCIOLI F, Pusiol T, Roncati L
Thin melanoma subtyping fits well with the American Joint Committee on Cancer staging system.
Melanoma Res. 2016;26:636.
PubMed Text format

PISCIOLI F, Pusiol T, Roncati L
Histopathological determination of thin melanomas at risk for metastasis.
Melanoma Res. 2016;26:635.
PubMed Text format

November 2016

LEONTOVICH AA, Dronca RS, Nevala WK, Thompson MA, et al
Effect of the lymphocyte-to-monocyte ratio on the clinical outcome of chemotherapy administration in advanced melanoma patients.
Melanoma Res. 2016.
PubMed Text format Abstract available

October 2016

PAOLINO G, Panetta C, Cota C, Didona D, et al
Vitamin D receptor immunohistochemistry variability in sun-exposed and non-sun-exposed melanomas.
Melanoma Res. 2016.
PubMed Text format Abstract available

SHOUSHTARI AN, Bluth MJ, Goldman DA, Bitas C, et al
Clinical features and response to systemic therapy in a historical cohort of advanced or unresectable mucosal melanoma.
Melanoma Res. 2016.
PubMed Text format Abstract available

NGUYEN BH, Kuo J, Budiman A, Christie H, et al
Two cases of clinical myasthenia gravis associated with pembrolizumab use in responding melanoma patients.
Melanoma Res. 2016.
PubMed Text format Abstract available

VARTANIAN A, Baryshnikova M, Burova O, Afanasyeva D, et al
Inhibitor of vasculogenic mimicry restores sensitivity of resistant melanoma cells to DNA-damaging agents.
Melanoma Res. 2016.
PubMed Text format Abstract available

CHAKRAVARTI N, Ivan D, Trinh VA, Glitza IC, et al
High cytotoxic T-lymphocyte-associated antigen 4 and phospho-Akt expression in tumor samples predicts poor clinical outcomes in ipilimumab-treated melanoma patients.
Melanoma Res. 2016.
PubMed Text format Abstract available

LIM MS, Wang JH, Power DG, Redmond HP, et al
Inflammatory regulation of stem-like cells in melanoma.
Melanoma Res. 2016.
PubMed Text format Abstract available

ADAMS G, Foote M, Brown S, Burmeister B, et al
Adjuvant external beam radiotherapy after therapeutic groin lymphadenectomy for patients with melanoma: a dosimetric comparison of three-dimensional conformal and intensity-modulated radiotherapy techniques.
Melanoma Res. 2016.
PubMed Text format Abstract available

BOTTLAENDER L, Perier-Muzet M, Lapras V, Thomas L, et al
Tumor-free osteosclerotic lesions in patients treated for metastatic melanoma using BRAF inhibitors.
Melanoma Res. 2016.
PubMed Text format Abstract available

AMBER KT, Panganiban CM, Korta D, Feraudy S, et al
A case report of bullous pemphigoid associated with a melanoma and review of the literature.
Melanoma Res. 2016.
PubMed Text format Abstract available

MATHESON JA, Te Marvelde L, Mailer S, Speakman D, et al
Prospective evaluation of prognostic indicators for early recurrence of cutaneous melanoma.
Melanoma Res. 2016.
PubMed Text format Abstract available

September 2016

KUBECEK O, Kopecky J
Microsatellite instability in melanoma: a comprehensive review.
Melanoma Res. 2016.
PubMed Text format Abstract available

MIRJACIC MARTINOVIC KM, Babovic NL, Dzodic RR, Jurisic VB, et al
Beneficial in-vitro effects of interleukin-2, interleukin-12, and their combination on functional and receptor characteristics of natural killer cells in metastatic melanoma patients with normal serum lactate dehydrogenase levels.
Melanoma Res. 2016.
PubMed Text format Abstract available

April 2016

CHENG C, Yang HW, Shang JF, Li WW, et al
Identification of a small molecule that downregulates MITF expression and mediates antimelanoma activity in vitro.
Melanoma Res. 2016;26:117-24.
PubMed Text format Abstract available

WANG LE, Li C, Xiong P, Gershenwald JE, et al
4-nitroquinoline-1-oxide-induced mutagen sensitivity and risk of cutaneous melanoma: a case-control analysis.
Melanoma Res. 2016;26:181-7.
PubMed Text format Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Malignant Melanoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: